Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1797-1805

  Michaud, Kaleb ^a,b   Berglind, Niklas ^c   Franzén, Stefan ^c   Frisell, Thomas ^d   Garwood, Christopher ^e   Greenberg, Jeffrey D ^f,g   Ho, Meilien ^h   Holmqvist, Marie ^d   Horne, Laura ^h   Inoue, Eisuke ⁱ   Nyberg, Fredrik ^c,j   Pappas, Dimitrios A ^g,k   Reed, George ^g,l   Symmons, Deborah ^e,m   Tanaka, Eiichi ⁱ   Tran, Trung N ⁿ   Verstappen, Suzanne M M ^e   Wesby Van Swaay, Eveline ^c   Yamanaka, Hisashi ⁱ   Askling, Johan ^d,o  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^j UNIVERSITY OF GOTHENBURG   (Sweden)

^k University of Gothenburg ^*  (United States)

^l UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^m MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁿ MEDIMMUNE   (United States)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Cardiovascular Disease; Epidemiology; Outcomes research; Rheumatoid Arthritis

Indexed keywords

C REACTIVE PROTEIN; FOSTAMATINIB; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DAS28; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FEMALE; FOLLOW UP; GENDER; HEALTH ASSESSMENT QUESTIONNAIRE; HEART FAILURE; HEART INFARCTION; HUMAN; INDIA; JAPAN; LUNG EMBOLISM; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NORTH AMERICA; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SOUTH AND CENTRAL AMERICA; STANDARDIZATION; SWEDEN; SYSTEMATIC ERROR; UNITED KINGDOM; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; MYOCARDIAL INFARCTION; REGISTER; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; EUROPE; FEMALE; HUMANS; INDIA; JAPAN; LATIN AMERICA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SWEDEN; TREATMENT OUTCOME;

EID: 84958092529     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208698     Document Type: Article

References (26)

1. Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013;80:29-33.
2. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929-34.
3. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
4. Arts EE, Fransen J, den Broeder AA, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015;74:998-1003.
5. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
6. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
7. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5.
8. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004;110:1774-9.
9. Radovits BJ, Fransen J, Shamma SA, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010;62:362-70.
10. Ljung L, Askling J, Rantapaa-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014;16:R127.
11. Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken) 2014;66:1296-301.
12. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612-21.
13. Kremer JM. The CORRONA database. Autoimmun Rev 2006;5:46-54.
14. Eriksson JK, Askling J, Arkema EV. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data. Clin Exp Rheumatol 2014;32(Suppl 85):S-147-9.
15. Symmons DP, Barrett EM, Bankhead CR, et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9.
16. Nakajima A, Inoue E, Tanaka E, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 2010;39:360-7.
17. Nyberg F, Askling J, Berglind N, et al. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiol Drug Saf 2015;24:1121-32.
18. Verstappen SM, Askling J, Berglind N, et al. Methodological challenges when comparing demographic and clinical characteristics of international observational registries. Arthritis Care Res (Hoboken) 2015;67:1637-45.
19. Ng CS, Palmer CR. Assessing diagnostic confidence: a comparative review of analytical methods. Acad Radiol 2008;15:584-92.
20. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997;16:791-801.
21. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-18.
22. Vashisht P, Sayles H, Cannella A, et al. Generalizability of patients with rheumatoid arthritis in biologic clinical trials. Arthritis Care Res (Hoboken) 2016. In press.
23. Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE 2015;10:e0117952.
24. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449-55.
25. Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010;268:578-85.
26. Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008;35:1009-14.